Lung InflammationNCT05260827
The Effects of Heated Tobacco Products Use on Lung Function and Volatile Organic Compounds in Exhaled Air
A study testing Heated tobacco product in people with Lung Inflammation, run by Karolinska Institutet at 1 site in Sweden.
Trial summary
This is a human randomized controlled cross-over study where we investigate the effects of heated tobacco products (HTP) on lung function and on assessing volatile organic compounds in exhaled air. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Lung Inflammation
- What is being tested?
- Heated tobacco product
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteSweden
- Study dates
- 1 Oct 2021to 1 Feb 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy, free from medication
Who cannot join
- Any form of cardiovascular disease
- Any form of pulmonary disease like asthma or COPD
- Any form of systemic or chronic disorder like rheumatologic or metabolic diseases. - Symptoms of infection or inflammation within 4 weeks of the study
- Pregnancy
Trial locations and contacts
1 site in 1 country.
Sweden1 site
Institutionen för kliniska vetenskaper, Danderyds sjukhus
Danderyd, Stockholm County, 18288
About this study
This is a human randomized controlled cross-over study where we investigate the effects of heated tobacco products (HTP) on lung function and on assessing volatile organic compounds in exhaled air.
Read the detailed description
The World Health Organization estimates that smoking is one of the leading causes of premature death worldwide with an estimated 5-8 million lives lost annually due to tobacco usage.
Heated tobacco products (HTP) is a new form of tobacco products. HTP usually consists of a pod with tobacco that is mixed with glycerol which is inserted into a heating chamber. HTP is not combusted but only heated. Previous studies into smoking cessation with regular cigarettes and electronic cigarettes have suggested a risk for double usage instead of cessation, augmenting a nicotine addiction. There is a risk that HTP use simply enhances nicotine usage and smoking addiction.
There is limited data on the health effects of HTP. A majority of the studies available have reported conflicts of interest to manufacturers of HTP. It has been shown that aerosols from HTP contain toxic compounds and free radicals just as in regular cigarette smoke, albeit in lower concentrations (6-8). Furthermore, aerosols from HTP can spread in a room, enabling passive exposure (9). It has been shown that there is a decrease in harmful biomarkers in smokers that switch to HTP after 5 days of usage but also of a higher HTP consumption compared to regular smoking. There are few studies on effects of HTP in humans. We seek to assess the effects of HTP usage on lung function and the presence of volatile organic compounds in exhaled air using non invasive methods.
Subjects and criteria:
Twenty five male or female occasional tobacco users (age 18-40, maximum 10 cigarettes per month or 10 pouches of snus per month) will be included. They have to be healthy, having no preexisting conditions or take any medications. All subjects will have to complete a normal health declaration.
Methods:
In randomized cross-over fashion subjects will either inhale vapor (1 puff per minute for 30 minutes, total 30 puffs) from a HTP of the brand IQOS (IQOS 3 Multi, Philip Morris AB) or perform sham-smoking of HTP.
Baseline coitinine in the blood and volatile organic compounds in exhaled air will be measured. Subjects will then use HTP as described above. Exhaled air is collected following exhaling a full breath by the volunteer at normal speed through a disposable mouthpiece connected to an open 129 ml plastic cylinder with valve and manual piston (Bio-VOC-2 breath sampler, Markes International). The valve has a low resistance which makes it very easy to blow air through the cylinder. A filter cassette with gas sampling tubes is then connected to the cylinder where the last 129 ml of the exhaled air remains. Using the piston, the air is then emptied onto the pipe via the filter. The gas sampling tube and the filter are marked with unique markings, which can then be linked to a sample code. The procedure can now be repeated 1-4 times to collect additional exhaled air. The total sampling time is from 2-7 minutes depending on the number of repetitions. After each exposure, exhaled air is collected 3-4 times for approximately two hours.
The gas sampling tube contains an inert adsorbent material which, when heated (~ 300 ° C) in a oxygen-free carrier gas, releases the volatile organic substances trapped during sampling. The substances are then analyzed using gas chromatography connected to a mass spectrometer, where the intensity of the substances' different mass / charge ratios is collected. After calibrating the instrument's response to various substances, the concentration in the exhaled air is calculated. For substances where there is no reference substance, a quantification is performed against a reference substance with a known response factor and identification is carried out with criterion requirements for match factor by means of a deconvolution program (AMDIS) against data in a mass spectrum reference library from NIST. Preliminary own tests and method comparisons with previous studies indicate that the data material will contain in the order of 30-100 identified volatile organic compounds.
Specification of VOCs:
The exhaled air is analyzed for the following VOCs:
Acetaldehyde Acetic acid Acetic acid, methyl ester Acetone Acetonitrile Acetophenone Acrolein alpha-Pinene Benzaldehyde Benzene Benzene, 1-chloro-4-methyl- Benzene, bromopentafluoro- Benzoic acid Benzonitrile Butanal Butane, 2,3-dimethyl-2,3-dinitro- Butanoic acid, methyl ester Cyclohexane Cymene Decanal Decane Diethyl carbitol D-Limonene Etanol Ethene, 1,1-dichloro- Ethylbenzene Formamide, N,N-diethyl- Furan, 2-methyl- Furan, tetrahydro-3-methyl- Heptanal Hexanal Hexane Hexane, 2,2-dimethyl- Hexane, 3-methyl- Hexanoic acid Isoprene Isopropyl Alcohol Methacrolein Methanol Methylene chloride N-Ethylformamide Nitrogen gas Nonanal Nonane Octanal Octane p-Cymene Phenol Phthalic anhydride Propane, 1-(methylthio)- p-Xylene Silane, triethylfluoro- Styrene Sulfide, allyl methyl Sulfur dioxide Tetrahydrofuran Toluene Triethyl phosphate Undecanal 1,3-Dioxolane, 2-methyl-
1-Dodecene
- H-Pyrrole, 1-ethyl- 1-Propene, 1-(methylthio)-, (E)- 1-Propene, 2-methyl- 2,2-Dimethoxybutane 2,3-Butanedione 2-Butanone 2-Ethylacrolein 2-Pentanone 2-Propanol, 2-methyl- 3-Pentanone 5-Hepten-2-one, 6-methyl-
- Conditions
- Lung Inflammation
- Being tested
- Heated tobacco product
- Keywords
- lung function, volatile organic compounds, exhaled air, Heated tobacco products
- Medical subject headings
- Pneumonia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Heated tobacco productOther
Sham heated tobacco product
| Study group | Role | What they receive |
|---|---|---|
| Heated tobacco product | Experimental | 30 puffs of heated tobacco product IQOS Receives: Other: Heated tobacco product |
| Sham | Experimental | sham heated tobacco product Receives: Other: Heated tobacco product |
What is being measured
The primary outcome is the main question the study is designed to answer.
Volatile organic compounds in exhaled air, nanogram/l (please see study description for specification of VOC)
in exhaled air
Measured: preexposure
Volatile organic compounds in exhaled air, nanogram/l (please see study description for specification of VOC)
in exhaled air
Measured: 10 minutes
Volatile organic compounds in exhaled air, nanogram/l (please see study description for specification of VOC)
in exhaled air
Measured: 30 minutes
Volatile organic compounds in exhaled air, nanogram/l (please see study description for specification of VOC)
in exhaled air
Measured: 120 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Mar 2022
- Study start1 Oct 2021
- Primary completion1 Oct 2022
- Study completion1 Feb 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung InflammationStudies of the same condition, open and under way.
- More trials run by Karolinska InstitutetThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Randomised controlled cross-over study
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Karolinska Institutet
- Sponsor type
- University, hospital or other
- Collaborators
- Swedish Heart Lung Foundation
- Responsible party
- Principal investigator, Magnus Lundbäck, Karolinska Institutet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05260827
- Sponsor's protocol ID
- Karolinska Institutet 2
- Status last verified
- Mar 2024
- First submitted
- 8 Oct 2021
- Last updated
- 8 Mar 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effects of Heated Tobacco Products Use on Lung Function and Volatile Organic Compounds in Exhaled Air
- ClinicalTrials.gov ID
- NCT05260827
- Acronym / sponsor ID
- Karolinska Institutet 2
- Conditions
- Lung Inflammation
- Keywords
- lung function, volatile organic compounds, exhaled air, Heated tobacco products
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Karolinska InstitutetUniversity, hospital or other
- Collaborators
- Swedish Heart Lung Foundation
- Study start
- 1 Oct 2021 (actual)
- Primary completion
- 1 Oct 2022 (actual)
- Study completion
- 1 Feb 2023 (actual)
- First posted
- 2 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a human randomized controlled cross-over study where we investigate the effects of heated tobacco products (HTP) on lung function and on assessing volatile organic compounds in exhaled air.
Detailed description
The World Health Organization estimates that smoking is one of the leading causes of premature death worldwide with an estimated 5-8 million lives lost annually due to tobacco usage.
Heated tobacco products (HTP) is a new form of tobacco products. HTP usually consists of a pod with tobacco that is mixed with glycerol which is inserted into a heating chamber. HTP is not combusted but only heated. Previous studies into smoking cessation with regular cigarettes and electronic cigarettes have suggested a risk for double usage instead of cessation, augmenting a nicotine addiction. There is a risk that HTP use simply enhances nicotine usage and smoking addiction.
There is limited data on the health effects of HTP. A majority of the studies available have reported conflicts of interest to manufacturers of HTP. It has been shown that aerosols from HTP contain toxic compounds and free radicals just as in regular cigarette smoke, albeit in lower concentrations (6-8). Furthermore, aerosols from HTP can spread in a room, enabling passive exposure (9). It has been shown that there is a decrease in harmful biomarkers in smokers that switch to HTP after 5 days of usage but also of a higher HTP consumption compared to regular smoking. There are few studies on effects of HTP in humans. We seek to assess the effects of HTP usage on lung function and the presence of volatile organic compounds in exhaled air using non invasive methods.
Subjects and criteria:
Twenty five male or female occasional tobacco users (age 18-40, maximum 10 cigarettes per month or 10 pouches of snus per month) will be included. They have to be healthy, having no preexisting conditions or take any medications. All subjects will have to complete a normal health declaration.
Methods:
In randomized cross-over fashion subjects will either inhale vapor (1 puff per minute for 30 minutes, total 30 puffs) from a HTP of the brand IQOS (IQOS 3 Multi, Philip Morris AB) or perform sham-smoking of HTP.
Baseline coitinine in the blood and volatile organic compounds in exhaled air will be measured. Subjects will then use HTP as described above. Exhaled air is collected following exhaling a full breath by the volunteer at normal speed through a disposable mouthpiece connected to an open 129 ml plastic cylinder with valve and manual piston (Bio-VOC-2 breath sampler, Markes International). The valve has a low resistance which makes it very easy to blow air through the cylinder. A filter cassette with gas sampling tubes is then connected to the cylinder where the last 129 ml of the exhaled air remains. Using the piston, the air is then emptied onto the pipe via the filter. The gas sampling tube and the filter are marked with unique markings, which can then be linked to a sample code. The procedure can now be repeated 1-4 times to collect additional exhaled air. The total sampling time is from 2-7 minutes depending on the number of repetitions. After each exposure, exhaled air is collected 3-4 times for approximately two hours.
The gas sampling tube contains an inert adsorbent material which, when heated (~ 300 ° C) in a oxygen-free carrier gas, releases the volatile organic substances trapped during sampling. The substances are then analyzed using gas chromatography connected to a mass spectrometer, where the intensity of the substances' different mass / charge ratios is collected. After calibrating the instrument's response to various substances, the concentration in the exhaled air is calculated. For substances where there is no reference substance, a quantification is performed against a reference substance with a known response factor and identification is carried out with criterion requirements for match factor by means of a deconvolution program (AMDIS) against data in a mass spectrum reference library from NIST. Preliminary own tests and method comparisons with previous studies indicate that the data material will contain in the order of 30-100 identified volatile organic compounds.
Specification of VOCs:
The exhaled air is analyzed for the following VOCs:
Acetaldehyde Acetic acid Acetic acid, methyl ester Acetone Acetonitrile Acetophenone Acrolein alpha-Pinene Benzaldehyde Benzene Benzene, 1-chloro-4-methyl- Benzene, bromopentafluoro- Benzoic acid Benzonitrile Butanal Butane, 2,3-dimethyl-2,3-dinitro- Butanoic acid, methyl ester Cyclohexane Cymene Decanal Decane Diethyl carbitol D-Limonene Etanol Ethene, 1,1-dichloro- Ethylbenzene Formamide, N,N-diethyl- Furan, 2-methyl- Furan, tetrahydro-3-methyl- Heptanal Hexanal Hexane Hexane, 2,2-dimethyl- Hexane, 3-methyl- Hexanoic acid Isoprene Isopropyl Alcohol Methacrolein Methanol Methylene chloride N-Ethylformamide Nitrogen gas Nonanal Nonane Octanal Octane p-Cymene Phenol Phthalic anhydride Propane, 1-(methylthio)- p-Xylene Silane, triethylfluoro- Styrene Sulfide, allyl methyl Sulfur dioxide Tetrahydrofuran Toluene Triethyl phosphate Undecanal 1,3-Dioxolane, 2-methyl-
1-Dodecene
- H-Pyrrole, 1-ethyl- 1-Propene, 1-(methylthio)-, (E)- 1-Propene, 2-methyl- 2,2-Dimethoxybutane 2,3-Butanedione 2-Butanone 2-Ethylacrolein 2-Pentanone 2-Propanol, 2-methyl- 3-Pentanone 5-Hepten-2-one, 6-methyl-
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (investigator)
- Number of arms
- 2
- Model description
- Randomised controlled cross-over study
| Arm | Type | Receives |
|---|---|---|
| Heated tobacco product | Experimental | Other: Heated tobacco product30 puffs of heated tobacco product IQOS |
| Sham | Experimental | Other: Heated tobacco productsham heated tobacco product |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Healthy, free from medication
Key exclusion criteria (4 listed)
- Any form of cardiovascular disease
- Any form of pulmonary disease like asthma or COPD
- Any form of systemic or chronic disorder like rheumatologic or metabolic diseases. - Symptoms of infection or inflammation within 4 weeks of the study
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Heated tobacco productSham heated tobacco product | Other | Heated tobacco product, Sham |
Primary outcome
Volatile organic compounds in exhaled air, nanogram/l (please see study description for specification of VOC)
Time frame: preexposure
in exhaled air
Volatile organic compounds in exhaled air, nanogram/l (please see study description for specification of VOC)
Time frame: 10 minutes
in exhaled air
Volatile organic compounds in exhaled air, nanogram/l (please see study description for specification of VOC)
Time frame: 30 minutes
in exhaled air
Volatile organic compounds in exhaled air, nanogram/l (please see study description for specification of VOC)
Time frame: 120 minutes
in exhaled air
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Mar 2024.
- Individual participant dataSharing planned: No
Related trials for Lung Inflammation
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
Active, not recruiting
CT for Personalized Mechanical Ventilation
Ventilator-Induced Lung Injury, Sepsis Syndrome
RecruitingPhase 3
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Asthma Control
RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Heated tobacco product in people with Lung Inflammation, run by Karolinska Institutet at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Volatile organic compounds in exhaled air, nanogram/l (please see study description for specification of VOC) (time frame: preexposure). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Mar 2024.